Amgen (AMGN) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $229.53B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Drug Manufacturers - General |
| Country | US | CEO | Robert A. Bradway |
| IPO Date | 1983-06-17 | CAGR | 20.51% |
| Employees | 31,500 | Website | www.amgen.com |
| Div. Yield | 1.89% | Payout Ratio | 60% |
| Buy Back Yield | — | Total Yield | 1.89% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $249.96B | P/E | 19.01 | Forward P/E | 17.45 | PEG | 0.4 |
| P/S | 7.33 | P/B | 23.96 | P/CF | 22.43 | P/FCF | 27.52 |
| Sales | $38.12B | Sales 1Y | 9.23% | Sales 3Y | 43.42% | Sales 5Y | 49.6% |
| EPS | $22.37 | EPS 1Y | 31.56% | EPS 3Y | 8.5% | EPS 5Y | 63.68% |
| Sales QoQ | 16.66% | EPS QoQ | 30.84% | Sales QoQ Avg | 2.89% | EPS QoQ Avg | 33.06% |
| Gross Margin | 72.65% | Operating Margin | 33.18% | Profit Margin | 22.93% | ROCE | 18.03% |
| ROA | 9% | ROE | 89% | Altman Z Score | 2.22 | Piotroski Score | 8 |
| Current Ratio | 1.37 | Quick Ratio | 1.13 | Cash Ratio | 0.55 | Op. CF Ratio | 0.16 |
| Debt/Equity | 4.9 | Debt/Assets | 0.6 | Lt Debt/Equity | 4.44 | Lt Debt/Cap. | 0.82 |
| Intrst Cov. | 4.74 | Inventory Turnover | 1.68 | Asset Turnover | 0.4 | Receivables Turnover | 3.73 |
| Enterprise Value | $249.96B | P/E Ratio | 19.01 |
| Forward P/E | 17.45 | PEG Ratio | 0.4 |
| P/S Ratio | 7.33 | P/B Ratio | 23.96 |
| P/CF Ratio | 22.43 | P/FCF Ratio | 27.52 |
| EPS | $22.37 | EPS Growth 1Y | 31.56% |
| EPS Growth 3Y | 8.5% | EPS Growth 5Y | 63.68% |
| Revenue Growth 1Y | 9.23% | Gross Margin | 0.73% |
| Operating Margin | 0.33% | Profit Margin | 0.23% |
| ROE | 0.89% | ROA | 0.09% |
| ROCE | 0.18% | Current Ratio | 1.37 |
| Quick Ratio | 1.13 | Cash Ratio | 0.55 |
| Debt/Equity | 4.9 | Interest Coverage | 4.74 |
| Altman Z Score | 2.22 | Piotroski Score | 8 |
Amgen (AMGN) valuation & financials
Amgen (AMGN) has a market capitalization of $229.53B and trades at a price-to-earnings ratio of 19.0. It operates in the Healthcare sector (Drug Manufacturers - General).
Amgen's revenue grew +9.2% over the last year.
Amgen's next earnings report is scheduled for November 3, 2026 after market close; analysts estimate EPS of $5.79. Check the earnings calendar to see all companies reporting this week.
Amgen (AMGN) — frequently asked questions
When does Amgen (AMGN) report earnings next?
Amgen is expected to report earnings on November 3, 2026 after market close. Analysts estimate EPS of $5.79.
What is Amgen's market cap?
Amgen (AMGN) has a market capitalization of $229.53B.
What is AMGN's P/E ratio?
Amgen trades at a price-to-earnings ratio of 19.0, with trailing twelve-month EPS of $22.37.
How fast is Amgen growing?
Amgen's revenue grew +9.2% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)